Glenview Trust co Reduces Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Glenview Trust co lessened its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 10.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,149 shares of the specialty pharmaceutical company’s stock after selling 500 shares during the quarter. Glenview Trust co’s holdings in Jazz Pharmaceuticals were worth $511,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in JAZZ. Victory Capital Management Inc. grew its position in Jazz Pharmaceuticals by 23.3% during the third quarter. Victory Capital Management Inc. now owns 253,299 shares of the specialty pharmaceutical company’s stock valued at $28,220,000 after buying an additional 47,807 shares during the period. CIBC Asset Management Inc bought a new stake in Jazz Pharmaceuticals during the third quarter valued at approximately $209,000. Natixis Advisors LLC grew its position in Jazz Pharmaceuticals by 7.6% during the third quarter. Natixis Advisors LLC now owns 22,834 shares of the specialty pharmaceutical company’s stock valued at $2,544,000 after buying an additional 1,603 shares during the period. Swiss National Bank grew its position in Jazz Pharmaceuticals by 0.3% during the third quarter. Swiss National Bank now owns 117,000 shares of the specialty pharmaceutical company’s stock valued at $13,035,000 after buying an additional 400 shares during the period. Finally, Advisors Asset Management Inc. grew its position in Jazz Pharmaceuticals by 3.9% during the third quarter. Advisors Asset Management Inc. now owns 9,624 shares of the specialty pharmaceutical company’s stock valued at $1,072,000 after buying an additional 364 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 1,140 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the sale, the chief accounting officer now owns 7,012 shares of the company’s stock, valued at $966,323.72. This represents a 13.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CMO Robert Iannone sold 7,080 shares of the company’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the sale, the chief marketing officer now directly owns 82,024 shares in the company, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock valued at $4,022,825 over the last 90 days. 4.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on JAZZ. Truist Financial boosted their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Morgan Stanley reiterated an “overweight” rating and issued a $183.00 price target (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Royal Bank of Canada dropped their price target on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Finally, Barclays reiterated an “overweight” rating and issued a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $187.71.

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $140.22 on Tuesday. The company has a market capitalization of $8.52 billion, a PE ratio of 19.75, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company’s fifty day moving average price is $129.88 and its 200-day moving average price is $121.01. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $148.06.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.